CSL Vifor lays off 85 in US commercial group in wake of $11.7B buyout


CSL Vifor, a subsidiary of Australian biotech giant CSL, is undergoing significant workforce changes in the wake of its $11.7 billion acquisition of Vifor Pharma last year. The company is set to lay off 85 employees based in California, according to a California Worker Adjustment and Retraining Notification.

CSL Vifor, previously known as Vifor Pharma, specializes in iron deficiency and kidney disease treatments. Following the acquisition, the company conducted a strategic review and concluded that adjustments were necessary within its U.S. commercial group to align with its current product portfolio and future growth prospects. These changes aim to deliver cost, revenue, and growth synergies.

The affected employees are expected to leave the company on October 25. CSL Vifor is encouraging them to explore opportunities within CSL Vifor or other divisions of CSL.

Workforce restructuring is a common practice following large-scale acquisitions as companies seek to streamline operations, reduce duplication, and optimize resources. In this case, CSL Vifor is taking steps to ensure its long-term success in the evolving healthcare landscape.

This development is similar to other acquisitions in the pharmaceutical and biotech industry, where companies have trimmed their workforce post-acquisition to align with their strategic goals and objectives. For example, Gilead Sciences reduced its workforce at the former Immunomedics headquarters after acquiring the company, and Merck made adjustments to the Acceleron workforce following its acquisition of the company.

Related Stories